Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

11.1%

3 terminated/withdrawn out of 27 trials

Success Rate

81.3%

-5.3% vs industry average

Late-Stage Pipeline

7%

2 trials in Phase 3/4

Results Transparency

23%

3 of 13 completed trials have results

Key Signals

3 recruiting3 with results

Enrollment Performance

Analytics

Phase 2
15(60.0%)
Phase 1
6(24.0%)
Phase 3
1(4.0%)
N/A
1(4.0%)
Early Phase 1
1(4.0%)
Phase 4
1(4.0%)
25Total
Phase 2(15)
Phase 1(6)
Phase 3(1)
N/A(1)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (27)

Showing 20 of 27 trials
NCT06578559Phase 2Active Not Recruiting

Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC

Role: collaborator

NCT06887088Phase 2Recruiting

Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases

Role: collaborator

NCT05706779Phase 2Recruiting

Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer

Role: collaborator

NCT03275311Recruiting

Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008

Role: collaborator

NCT05252988Phase 2Active Not Recruiting

Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib

Role: collaborator

NCT03518606Phase 1Completed

Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours

Role: collaborator

NCT03864042Phase 1Completed

Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors

Role: collaborator

NCT05446142Phase 1Completed

A Relative Bioavailability Study Evaluating Two New Encorafenib Formulations

Role: collaborator

NCT02585388Phase 2Terminated

Addition of Aromatase at the Navelbine in Pretreated Metastatic Breast Cancer.

Role: collaborator

NCT03878719Phase 1Terminated

Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma

Role: collaborator

NCT05767879Phase 2Unknown

(Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma

Role: collaborator

NCT03032055Unknown

Validation of a Predictive Score of Acute Chest Syndrome

Role: collaborator

NCT02139904Phase 2Completed

Vinorelbine in Mesothelioma

Role: collaborator

NCT02197637Phase 2Completed

Phase II Trial of Oral Vinorelbine in Children With Recurrent or Progressive Unresectable Low-Grade Glioma

Role: collaborator

NCT01844947Phase 1Completed

Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract

Role: collaborator

NCT00863460Phase 2Active Not Recruiting

Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients

Role: collaborator

NCT02802748Early Phase 1Completed

Phase 0 Study of Metronomic Oral Vinorelbine and Letrozole in HR+/HER2-negative Early Breast Cancer Patients (VENTANA)

Role: collaborator

NCT01029678Phase 2Completed

Concomitant Radio-chemotherapy in the Elderly

Role: collaborator

NCT02919462Phase 2Terminated

Open-label, Multicenter, Randomized Phase II Trial of Treatment With Cisplatin and Pemetrexed or Cisplatin and Oral Vinorelbine in Chemotherapy Naïve Patients Affected by Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer With High Thymidylate Synthase Expression

Role: collaborator

NCT01941771Phase 2Completed

Phase II Trial With Metronomic, Capecitabine Plus Oral Vinorelbine for Metastatic Breast Cancer

Role: collaborator